Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

increased risk of bleeding. [2020] 1.3.10 Do not routinely offer self-management or self-monitoring of INR to people who have had DVT or PE and are having treatment with a VKA. [2012] Anticoagulation treatment for DVT or PE in people at extremes of body weight 1.3.11 Consider anticoagulation treatment with regular monitoring of therapeutic levels for people with confirmed proximal DVT or PE who weigh less than 50 kg or more than 120 kg, to ensure effective anticoagulation. Note the cautions and requirements for dose adjustment and monitoring in the medicine's summary of product characteristics (SPC), and follow locally agreed protocols or advice from a specialist or multidisciplinary team. [2020] Anticoagulation treatment for PE with haemodynamic instability 1.3.12 For people with confirmed PE and haemodynamic instability, offer continuous UFH infusion and consider thrombolytic therapy (see the section on thrombolytic therapy). [2020] Anticoagulation treatment for DVT or PE with renal impairment or established renal failure In March 2020, some LMWHs were off label for the treatment of DVT or PE in people with severe renal impairment (estimated creatinine clearance 15 ml/min to 30 ml/min) or established renal failure (estimated creatinine clearance less than 15 ml/min). See NICE's information on prescribing medicines. 1.3.13
